The National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) is the largest BRC outside the South East of England and the beating heart of translational research across Greater Manchester, Lancashire and South Cumbria, transforming scientific breakthroughs into diagnostic tests and life-saving treatments for patients.
Awarded more than £60 million (2022-27) – the largest single research award given by the NIHR to the city region – Manchester BRC brings together world-leading researchers based at The University of Manchester and six of the country’s foremost NHS Trusts, with a vision to drive health improvements and lasting change for all through creative, inclusive and proactive research that identifies and bridges gaps between new discoveries and individualised care.
Manchester BRC is driving forward pioneering research in the areas of cancer (prevention and early detection, advanced radiotherapy, precision medicine, living with and beyond cancer), inflammation (rheumatic and musculoskeletal disease, respiratory medicine, dermatology, integrative cardiovascular medicine), high-burden under-researched conditions (hearing health, mental health, rare conditions) and advanced diagnostics and therapeutics (next generation phenotyping and diagnostics, next generation therapeutics).
Researchers at The University of Manchester in collaboration with Manchester University NHS Foundation Trust are launching a new Cystic Fibrosis Innovation Hub to accelerate the development of new tests and treatment approaches for lung infections.
Low dose morphine has the potential to treat chronic cough in people with idiopathic pulmonary fibrosis, according to new research from NIHR Manchester BRC and NIHR Imperial BRC.
There are plently of opportunities for people to help shape our research plans.
Research is vital to help us understand more about a particular disease or condition and how to treat them.